Author details

Full Name

Joanne Xiu

Affiliation

ORCID

Career Start Year

2002

Papers

112

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37034762	Multi-omic characterization reveals a distinct molecular landscape in young-onset pancreatic cancer.		2023
37853341	Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.	BMC Cancer	2023
37677121	Opposing Roles of <i>SPOP</i> Mutations in Human Prostate and Endometrial Cancers.	JCO Precis Oncol	2023
37944072	Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer.		2023
37964004	Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases.		2023
37683549	Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 "Lynch-like" mismatch repair gene mutation.		2023
36968078	Identification of actionable targets for breast cancer intervention using a diversity outbred mouse model.		2023
37147496	Activity of pemetrexed in pre-clinical chordoma models and humans.	Sci Rep	2023
37400502	PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system.		2023
37327205	Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study.		2023
37131274	The Genomic Landscape of Vulvar Squamous Cell Carcinoma.		2023
36629137	Peritoneal metastases from primary appendiceal and colorectal carcinomas demonstrate distinct molecular identities on comprehensive tumor analysis.		2023
37126020	Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.	Clin Cancer Res	2023
36681091	Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study.	Lancet Oncol	2023
37516008	Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset.		2023
37291277	Capicua (CIC) mutations in gliomas in association with MAPK activation for exposing a potential therapeutic target.		2023
34725190	Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers.	Molecular Cancer Therapeutics	2022
36112544	Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets.	Clin Cancer Res	2022
35821680	Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields.	Neuro-Oncology Advances	2022
36082279	Characterization of Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing.	JTO Clinical and Research Reports	2022
35491653	Association of TP53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer.	Clinical Cancer Research	2022
35490034	Molecular profiles of endometrial cancer tumors among Black patients.	Gynecologic Oncology	2022
36557020	<i>BRCA1/2</i> Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.	Medicina (Kaunas)	2022
34801409	The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.	Clinical Lung Cancer	2022
34469533	Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.	Journal of the National Cancer Institute	2022
35302596	Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.	Clinical Cancer Research	2022
35254413	Comprehensive Analysis of R-Spondin Fusions and RNF43 Mutations Implicate Novel Therapeutic Options in Colorectal Cancer.	Clinical Cancer Research	2022
34728807	Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer.	Oncogene	2022
34482103	Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC).	Lung Cancer	2021
33707526	Pan-cancer analysis of RNA expression of ANGIOTENSIN-I-CONVERTING ENZYME 2 reveals high variability and possible impact on COVID-19 clinical outcomes.	Scientific Reports	2021
33798656	Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.	Ann Oncol	2021
34117033	Clinical and Functional Characterization of Atypical <i>KRAS</i>/<i>NRAS</i> Mutations in Metastatic Colorectal Cancer.	Clin Cancer Res	2021
34063999	Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of .	Cells	2021
33741265	TERT Gene Fusions Characterize a Subset of Metastatic Leydig Cell Tumors.	Clin Genitourin Cancer	2021
34163031	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer.	Oncogene	2021
34162346	Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling.	BMC Neurol	2021
33465745	Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type.	Transl Oncol	2021
34154791	Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib.	Journal of Thoracic Oncology	2021
33766816	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer.	Clin Cancer Res	2021
33087512	The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer.	Mol Cancer Ther	2021
33293373	Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer.	Clin Cancer Res	2021
34518295	Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.	Mol Cancer Ther	2021
34917263	Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas.	Oncotarget	2021
34790403	Molecular characterization of squamous cell carcinoma of the anal canal.	Journal of Gastrointestinal Oncology	2021
34788629	Evaluating the impact of age on immune checkpoint therapy biomarkers.	Cell Rep	2021
34563366	Assessment of immune biomarkers and establishing a triple negative phenotype in gynecologic cancers.	Gynecologic Oncology	2021
34562615	Predicted Immunogenicity of CDK12 Biallelic Loss-of-Function Tumors Varies across Cancer Types.	J Mol Diagn	2021
34391386	Correction to: Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling.	BMC Neurol	2021
34433020	Evaluating the impact of age on immune checkpoint therapy biomarkers.	Cell Rep	2021
34707195	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients.	npj Precision Oncology	2021